NovaBay Pharmaceuticals, Inc.
NBY
$0.58
-$0.02-3.33%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 31.02% | 22.15% | -84.82% | 49.94% | -1,191.91% |
| Total Depreciation and Amortization | 0.00% | 16.99% | -7.69% | -59.35% | -20.17% |
| Total Amortization of Deferred Charges | -78.10% | -31.95% | -- | -- | -- |
| Total Other Non-Cash Items | -97.06% | 8.71% | 2,015.56% | -52.72% | 206.86% |
| Change in Net Operating Assets | -891.96% | 133.77% | -18.57% | -58.66% | 88.48% |
| Cash from Operations | -466.21% | 68.64% | -10.37% | 74.03% | 78.45% |
| Capital Expenditure | -100.00% | 0.00% | 84.62% | -- | 98.75% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -100.00% | 0.00% | 8,315.38% | -- | 98.75% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -36.92% | -222.28% | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 67.35% | -- | -- | -- |
| Cash from Financing | 462.05% | -119.58% | -- | -100.86% | -133.88% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 102.13% | -264.42% | 19.52% | -118.73% | -1,746.97% |
